Stocks and Investing Stocks and Investing
Tue, January 9, 2024

Bradley Canino Maintained (BPMC) at Strong Buy with Increased Target to $97 on, Jan 9th, 2024


Published on 2024-10-28 08:16:12 - WOPRAI, Bradley Canino
  Print publication without navigation


Bradley Canino of Stifel, Maintained "Blueprint Medicines Corporation" (BPMC) at Strong Buy with Increased Target from $95 to $97 on, Jan 9th, 2024.

Bradley has made no other calls on BPMC in the last 4 months.



There are 7 other peers that have a rating on BPMC. Out of the 7 peers that are also analyzing BPMC, 2 agree with Bradley's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Michael Ulz of "Morgan Stanley" Maintained at Hold with Increased Target to $63 on, Friday, October 27th, 2023
  • Peter Lawson of "Barclays" Maintained at Hold with Increased Target to $58 on, Friday, October 27th, 2023


These are the ratings of the 5 analyists that currently disagree with Bradley


  • Dane Leone of "Raymond James" Maintained at Strong Buy with Increased Target to $100 on, Friday, December 22nd, 2023
  • Derek Archila of "Wells Fargo" Maintained at Buy with Increased Target to $115 on, Tuesday, December 19th, 2023
  • Andrew Fein of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $85 on, Monday, December 11th, 2023
  • Ami Fadia of "Needham" Maintained at Strong Buy with Increased Target to $74 on, Friday, October 27th, 2023
  • Matthew Biegler of "Oppenheimer" Upgraded from Hold to Buy and Held Target at $85 on, Friday, October 27th, 2023

Contributing Sources